Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00664625 · ClinicalTrials.gov registry record · Phase 1

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

A Phase 1 study of Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
6
Study locations

NCT00664625: Completed Phase 1 study of Chronic Hepatitis C, sponsored by Bristol-Myers Squibb.

NCT00664625 is a Phase 1 study of Chronic Hepatitis C that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00664625, a Phase 1 study of Chronic Hepatitis C, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
6
Study locations

Study Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG BMS-791325

Study Locations (6)

California

  • Advanced Clinical Res Inst - Anaheim
  • West Coast Clinical Trials, Llc - Cypress

Missouri

  • Washington University School Of Medicine - St Louis

Pennsylvania

  • University Of Pennsylvania - Philadelphia

Texas

  • Alamo Medical Research - San Antonio

Buenos Aires

  • Local Institution - Buenos Aires

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-05
Est. Completion 2009-06
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00664625 record still lists

NCT00664625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 213-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00664625 lists 6 locations in 5 states (California, Missouri, Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT00664625 about?

NCT00664625 is a clinical study titled "A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects". The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection

What is the current status of trial NCT00664625?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-05. Estimated completion is 2009-06.

What conditions does trial NCT00664625 study?

This clinical trial studies the following conditions: Chronic Hepatitis C.

What interventions are being tested in trial NCT00664625?

The interventions under investigation include: Placebo (DRUG), BMS-791325 (DRUG).

Who is sponsoring clinical trial NCT00664625?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00664625 being conducted?

This trial has 6 study locations across California, Missouri, Pennsylvania, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00664625's enrollment target sits among peer trials

24 14th of 16 higher than 3 of 16 other Chronic Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00664625, the US trial registry maintained by the National Library of Medicine. NCT00664625 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.